Additional file 1 of Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report

Additional file 1. Lab data

Factors that influenced choice of the syrup.

<p>Factors that influenced choice of the syrup.</p

List of the compositions of identified syrups cough syrups containing more than one active ingredient.

<p>List of the compositions of identified syrups cough syrups containing more than one active ingredient.</p

Details on the sex of the children, highest level of their mother’s education and proportions of those who have used any of the identified syrups, as well as the type of syrup.

<p><b>1°</b> - Primary school level of education</p><p><b>2°</b> - Secondary school level</p><p><b>3°</b> - Tertiary level (university, technical colleges etc).</p><p>Details on the sex of the children, highest level of their mother’s education and proportions of those who have used any of the identified syrups, as well as the type of syrup.</p

sj-docx-1-cat-10.1177_10760296231184216 - Supplemental material for Risk of Bleeding Associated With Outpatient Use of Rivaroxaban in VTE Management at a National Referral Hospital in Western Kenya

Supplemental material, sj-docx-1-cat-10.1177_10760296231184216 for Risk of Bleeding Associated With Outpatient Use of Rivaroxaban in VTE Management at a National Referral Hospital in Western Kenya by Dennis Njuguna, BPharm, Francis Nwaneri, MD, Allyson C. Prichard, PharmD, Imran Manji, BPharm, MPH, Gabriel Kigen, BPharm, MPhil, PhD, Naftali Busakhala, MBChB, MMed, Samuel Nyanje,BSc, Emily O'Neil, PharmD and Sonak D. Pastakia, PharmD, MPH, PhD in Clinical and Applied Thrombosis/Hemostasis</p

Prevalence and Nature of Clinically Significant Drug Interactions in Kenya.

<p> <b>*occurring in 334 individuals.</b></p

Factors Associated with Risk for Developing a Clinically Significant Drug Interaction.

<p>Summary statistics are based on original data (ignoring the missing observations). However, both the unadjusted (univariate) and adjusted (bivariate) odds ratios (and their 95% confidence intervals) were computed after a multiple imputation analysis (of 100 iterations) to replace the missing observations for age, CD4 count, weight and WHO Stage. The odds ratios were computed using logistic regression models (with all variables forced into the model in the adjusted/multivariate analysis).</p><p> <i>*: missing observations replaced using multiple imputation (100 iterations).</i></p

Risk of Clinically Significant Drug Interaction by Individual Drug.

<p> <b><i>‡: Fisher exact test.</i></b></p

Odds Ratios for Clinically Significant Drug Interaction by CD4 Count Decile.

<p>Odds Ratios for Clinically Significant Drug Interaction by CD4 Count Decile.</p